Mechanisms of Action of CJC-1295 and Ipamorelin

The One-Two Punch for Natural GH Release

People want growth hormone (GH) for recovery and fat loss, though that evidence comes from GH itself or user reports, not trials of these peptides. The old-school way was to inject exogenous GH. Effective, sure, but it's a blunt instrument: it suppresses your own production and overrides your natural pulsatile release.

Stacking CJC-1295 and ipamorelin takes a different approach. Instead of replacing your body's GH, it gets your pituitary to release more of its own. The two peptides work on different receptors. One loads the cannon, the other lights the fuse.

The Base Layer: How CJC-1295 Amplifies Your Potential

"CJC-1295" can mean two different products. CJC-1295 with DAC (Drug Affinity Complex) is the long-acting version tested in the 2006 human studies. What vendors sell as "CJC-1295 without DAC" is essentially Modified GRF 1-29 (Mod GRF 1-29), whose half-life is commonly cited as about 30 minutes, though we found no human study measuring it. So, if you're injecting something once or twice a week, you're using the version with DAC. If you're injecting it 2-3 times a day, you're likely using Mod GRF 1-29. This section covers the DAC version, the one with published human data.

CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog. Your hypothalamus naturally releases GHRH to tell your pituitary gland, "Hey, get ready to release some GH." CJC-1295 mimics that signal at the GHRH receptor on GH-producing cells (somatotrophs), but it lasts far longer.

The key is the DAC technology. A small chemical group is attached that allows the peptide to bind to albumin, the most abundant protein in your blood. This protects CJC-1295 from being broken down. In a 2006 study of healthy adults aged 21-61 (Teichman and colleagues), its half-life was 5.8-8.1 days, and one injection raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days.

Forum copy often says the DAC version causes a constant "GH bleed" that flattens natural pulses. The one human study that checked found otherwise. Ionescu and Frohman (2006) sampled GH every 20 minutes overnight in healthy men before and a week after one dose. Pulse frequency and size were unchanged; the trough between pulses rose 7.5-fold, lifting mean GH by 46% and IGF-1 by 45%. It's like turning up the gain on an amplifier while the rhythm keeps playing. That raised background loads the cannon.

The Trigger: Ipamorelin's Precision Strike

If CJC-1295 is the foundation, ipamorelin is the trigger. Ipamorelin is a Growth Hormone Releasing Peptide (GHRP), a five-amino-acid peptide first described by Novo Nordisk researchers in 1998.

GHRPs work through a completely different mechanism than GHRH. They bind to the ghrelin receptor (GHSR-1a) in the pituitary. This is the same receptor that the "hunger hormone" ghrelin binds to. Activating this receptor signals the pituitary to release its stored GH. It lights the fuse.

Ipamorelin's appeal comes from how it compared with its older relatives:

• GHRP-6: The original. It works, but users consistently report strong hunger (it hits the ghrelin receptor hard), and in a 1990 study of 18 healthy men it roughly doubled cortisol and prolactin at the top IV dose.
• GHRP-2: Active at lower doses than GHRP-6 in pigs, and it also raised cortisol. For lifters, chronically elevated cortisol is a concern because it's catabolic.

The selectivity claim comes from that 1998 rat and pig work (Raun and colleagues). Ipamorelin released GH about as well as GHRP-6 but didn't raise ACTH or cortisol beyond what GHRH did, even at more than 200 times the effective dose. (No GHRP in that study changed prolactin.) Human data are thinner: an IV study in 48 healthy men (half-life about 2 hours, GH release rising with dose) and one failed Phase 2 trial, neither designed to track cortisol or prolactin over weeks. "Selective" fairly describes the early animal results. Whether ipamorelin leaves other hormones alone in people hasn't been tested.

Why 1 + 1 = 5: Unpacking the Synergy

This is where it gets interesting. In that same 1990 study (Bowers and colleagues), low IV doses of GHRP-6 plus GHRH released more GH than the two would add up to separately, suggesting independent pathways. That's the human basis for the stack, though it used single IV doses of related compounds, not CJC-1295 and ipamorelin under the skin.

Here's the proposed mechanism:

1. CJC-1295 (the GHRH) keeps steady pressure on the GHRH receptor, raising the GH trough between pulses.
2. Ipamorelin (the GHRP) then triggers release through the ghrelin receptor and is thought to counter somatostatin, the hormone that acts as the "brake" on GH release (mainly animal evidence).

So you're hitting the gas while possibly easing the brake on a pituitary primed by CJC-1295. The output stays pulsatile, which users cite as the advantage over injected GH; whether that avoids desensitization over the long term hasn't been tested.

What the 2024 FDA Reviews Found

In late 2024, FDA reviewed both peptides for its 503A compounding list, and its advisory committee voted against each (0-13 for CJC-1295 in December, 0-12 for ipamorelin in October).

CJC-1295. In the first 2006 trial, 94% of participants had an adverse event after one injection, most often injection-site reactions (about 70%), along with headache and flushing-type vasodilatory reactions. The second trial reported dizziness and low blood pressure, and the Ionescu study noted a raised heart rate. FDA also cited anecdotal reports of a Phase 2 trial in HIV lipodystrophy, terminated after a participant died of a heart attack 2 hours after their 11th weekly dose. The physician blamed undiagnosed coronary disease, and the data were never published. FDA found no studies of effectiveness in people with GH deficiency.

Ipamorelin. Its only efficacy trial, a Phase 2 study of IV ipamorelin in 117 adults after abdominal surgery, missed its primary endpoint for postoperative ileus (median 25.3 vs 32.6 hours to a first tolerated meal, not significant). Development stopped. High blood sugar was more common in the ipamorelin group, as were low potassium and insomnia. Two people in that group died after treatment ended; FDA said causality was unclear.

Surgical patients on IV doses aren't healthy lifters, though the blood sugar signal fits what's expected from raising GH. Our overview of peptide health risks covers the wider class. As of October 2026, neither peptide is approved anywhere, and WADA's 2026 Prohibited List names both under S2, banned at all times for tested athletes (see peptides and anti-doping rules).

Protocols, Dosing, and Real-World Application

None of these protocols comes from a trial; they're what vendors and users describe. Our guide to reading reported peptide doses explains how to weigh them.

For CJC-1295 with DAC, vendor and community guides commonly list 500mcg to 1000mcg injected subcutaneously once or twice per week, often for 12-16 weeks, a range we couldn't trace to a primary source; the 2006 trials used 30-250 mcg/kg, best tolerated at 30-60 mcg/kg. For ipamorelin, vendor guidance lists 200-300 mcg 2-3 times a day for 8-12 weeks. Most forum users actually describe one bedtime dose of 100-300 mcg of each, using the no-DAC form of CJC-1295. The ipamorelin trials used IV doses by body weight (0.03 mg/kg twice daily in the Phase 2).

Community guides often group the stack by goal (user-described, not tested):

Some notes on these community practices:

• "Saturation dose": Community guides say ipamorelin saturates around 1mcg per kg of body weight (100mcg for a 100kg/220lb person), with little gained beyond 200-300mcg per injection. We couldn't trace that to a human study, and the IV study found GH rising with dose.
• Timing around meals: Users commonly report injecting at least 2 hours after the last meal and waiting 30 minutes before eating, because high blood sugar from a recent carbohydrate meal is thought to blunt GH release. That timing is untested for this stack.
• Cycles: Users describe running the stack for 8-16 weeks followed by a break of at least 4 weeks to keep the pituitary sensitive, a practice no study has tested.

What We Still Don't Know

As of October 2026, no trial of either peptide, alone or combined, has measured muscle or fat outcomes. We also found no published human data on the no-DAC form most people use, or on months of use in healthy adults. For how this pair fits the wider GH axis, see our growth hormone pathway explainer.